Our lab, together with others, have secured funding for a project titled “Making it personal”, which uses theatre to explore public perception of a new form of genetic testing. Read more below....
https://t.co/qO397AN68v
Introducing our latest paper (https://t.co/EuVGLoCmuM) : "can the male germline offer insight into mammalian brain expansion?"
Its contents in brief: we think so.
The genes that influence menopause timing are also linked to cancer risk and newly arising mutations in egg cells.
Balancing the benefits of future treatments to extend fertility with the potential risks will be important, says @GorielyLab. https://t.co/GLEvzEoGYw
After a few years of work, we have identified the first non RAS/MAPK pathway gene which is under 'selfish selection' in the male germline. With implications for those with @MyhreSyndrome, our seminal work is published in @AJHGNews
Hot off the press! Our latest publication “SMAD4 mutations causing Myhre syndrome are under positive selection in the male germline”, is out today in @AJHGnews! https://t.co/ooURFjoUJ5 – the result of a fruitful collaboration with the Tartaglia lab in Rome
SMAD4 is the first PAE gene operating outside the RAS-MAPK pathway @RASopathiesnet. This finding raises the exciting possibility that other genes and signalling pathways may be under positive selection in the male germline.
It's a momentous week: after 8 years in the Wilkie Lab, our former postdoc/visiting researcher @educalpena is leaving Oxford to become a Principal Investigator at @IISLaFe in Valencia 🧬🇪🇸
Congratulations to Edu, and farewell - we wish you the best of luck with your next steps!
We are grateful to all our participants and to our funders @OxfordBRC@Wellcometrust for making this research possible. Thank you also to our reviewers and editors at The Journal of Genetic Counseling for giving us the opportunity to share our findings. 10/10
Pregnancy decisions can be hard after having a child w/ a genetic condition. Latest @Gorielylab research on a new strategy:“Professionals’ views on providing personalized recurrence risks for de novo mutations”@AliMakesHay JWells @AGoriely NHallowell https://t.co/Y5XBxCfNrE 1/10
A further finding is that giving personalised risk information with a non-directive approach may create patient burden. Securing understanding for autonomous decision-making may be hard to achieve and couples may want more guidance. Research with couples is planned. 9/10